Cognition Therapeutics Inc. (CGTX), a clinical-stage neuroscience company, has two key catalysts to watch in the coming months.
The company's lead drug candidate is CT1812, an oral small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (s-2) receptor complex, a transmembrane protein known to be linked with neurodegenerative diseases and cancer development.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com